Navigation Links
Royalty Pharma Acquires Royalty Interest in RotaTeq(R) from The Children's Hospital Foundation for $182 Million
Date:4/24/2008

NEW YORK, April 24 /PRNewswire/ -- The Children's Hospital Foundation, the parent company of The Children's Hospital of Philadelphia(R), and Royalty Pharma announced today that the Foundation has sold its worldwide royalty interest in respect of sales of RotaTeq(R) from and after October 1, 2007, to Royalty Pharma for $182 million in cash.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061026/RPLOGO )

"With the addition of this royalty on RotaTeq(R), we further our strategy of building a highly diversified portfolio of royalty interests on leading biopharmaceutical products. We are pleased to add the first vaccine to complement our royalties on products that treat a wide range of diseases, including cancer, rheumatoid arthritis and other autoimmune disorders, AIDS/HIV and neuropathic pain," said Pablo Legorreta, Chief Executive Officer of Royalty Pharma. "More important, we are partnering with the world's best research hospitals, universities and biopharmaceutical companies, and providing them with critical sources of financing that they can employ in further research and development endeavors. This will result, hopefully, in continued innovation and therapeutic alternatives for patients."

"CHOP will use this money in the continual pursuit of advancing science to benefit children," said Steven M. Altschuler, MD, President and Chief Executive Officer, The Children's Hospital of Philadelphia(R).

RotaTeq(R) is a live, oral pentavalent vaccine indicated for the prevention of rotavirus gastroenteritis. RotaTeq(R) was approved by the United States Food and Drug Administration in February 2006, has been approved in 70 other countries and has launched in 42 of these countries. It is marketed by Merck & Co. Inc. RotaTeq(R) was created as a result of research jointly performed by The Children's Hospital of Philadelphia(R) and The Wistar Institute, Philadelphia, PA.
'/>"/>

SOURCE Royalty Pharma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
2. Drug Royalty Corporation Changes Its Name to DRI Capital
3. Cowen Group, Inc. and Cowen Healthcare Royalty Partners Announce Expansion of Royalty Investment Team
4. Cowen Group, Inc. and Cowen Healthcare Royalty Partners Announce Expansion of Royalty Investment Team
5. Antibody Engineering Company F-Star Buys Back Royalty Obligations
6. CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection
7. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
8. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
11. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... and BANGALORE, India , July ... profiling company that uses next generation sequencing technology to ... Scott A. Storrer as chief executive officer. In ... will be responsible for all strategy, business expansion and ... who has served as Strand,s chairman and CEO since ...
(Date:7/1/2015)... Ariz. , July 1, 2015 Isagenix ... it has earned three Gold, three Silver, and three ... Awards gala held in Chicago ... as the premier business awards program in the U.S. ... recognizes our company,s strength in developing leaders, cultivating talent, ...
(Date:7/1/2015)... ... July 01, 2015 , ... Apex Therapeutics announced today that company CEO, ... PA. , The presentation took place on Tuesday, June 16 and provided ... development of APX3330 for the treatment of pancreatic cancer. A copy of the ...
(Date:6/30/2015)... -- R-Japan Co.,Ltd. obtained the license of cell processing facility ... the Ministry of Health, Labour and Welfare Kinki Bureau of ... The fact that R- Japan received the ... and Medical Devices Agency (PMDA) on May 18, 2015 two ... cell manufacturing service to medical institutions. As of November 25, ...
Breaking Biology Technology:Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2
... Wilmington, DE (PRWEB) May 5, 2009 -- The ... group vice president -- DuPont Applied BioSciences ... the biofuels industry that ranges from the advanced ... the new advanced biofuels technologies we are bringing ...
... Inc., a clinical-stage biopharmaceutical company focused on diseases of ... 1B trial for SQ109 with the dosing of the ... intended to replace one or more of the current ... U.S. FDA Fast Track designation and FDA/EMEA Orphan Drug ...
... Syrinx Consulting Corporation , an IT consulting ... SharePoint applications , announced today that ... a leading biopharmaceutical company in the Boston area. ... gigabytes of data from a SharePoint 2003 environment to ...
Cached Biology Technology:DuPont Statement on Obama Administration Biofuels Interagency Working Group 2DuPont Statement on Obama Administration Biofuels Interagency Working Group 3Sequella Commences Phase 1B Study for New Tuberculosis Drug SQ109 2Syrinx Wins Contract with Leading Pharmaceutical Company for SharePoint 2007 Services 2
(Date:6/17/2015)... GERMANTOWN, Maryland , June 17, 2015 ... Produktlinie mit DNA-Tests verbessert den Analyseprozess und senkt Laborkosten ... Frankfurt Prime Standard: QIA) hat heute in den ... Investigator ® für die forensische ... Kits zur Erstellung genetischer Fingerabdrücke bieten eine integrierte Lösung ...
(Date:6/17/2015)... Calif. , June 17, 2015  Synaptics ... human interface solutions, today announced that Xiaomi, one ... the Synaptics ® ClearPad ® family ... display driver integrated circuits (DDICs) for its latest ... By leveraging ClearPad for full in-cell display solutions ...
(Date:6/16/2015)... June 16, 2015 /CNW Telbec/ - handyem Inc. ... around the incorporation of handyem,s HPC-150 portable flow ... the Mo-POD™. This unprecedented model of mobile laboratory ... at the Pennsylvania Convention ... 15 th to 18 th 2015. ...
Breaking Biology News(10 mins):QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3
... supply based on biomass grown to generate electricity and ... Jrgen O. Metzger from Carl von Ossietzky University of ... University of Goettingen in Germany, it is both a ... suggests it is unrealistic. Their findings(1) are published online ...
... know that poor diet and lack of exercise can lead ... is not just the heart that is affected blood ... pain when walking, immobility and even in extreme cases, amputation. ... artery disease (PAD) once we are 65 or over, and ...
... sensors for cancer drugs and other DNA-damaging agents inside ... wrapped in DNA, can detect chemotherapy drugs such as ... that damage DNA. "We,ve made a sensor that ... and actually detect several different classes of molecules that ...
Cached Biology News:Turning over a new leaf for future energy supplies 2MIT nanotubes sniff out cancer agents in living cells 2
Form: Ready to use Applications: ELISA...
Form: Ready to use Applications: ELISA...
X-prolyl aminopeptidase (aminopeptidase P) 1, soluble...
2,4,6, Trinitrophenyl hapten is conjugated to lipopolysaccharide (LPS)....
Biology Products: